Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor 3 4 5 6
1 2
Akira Takeshita1, Junko Igarashi-Migitaka2, Noriyuki Koibuchi3, and Yasuhiro Takeuchi1
7 8 9 10 11 12 13 14 15 16 17 18 TEL: +81-3-3588-1111
1Endocrine Center, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo 105-8470, Japan
2Department of Anatomy and Cell Biology, St. Marianna University School of Medicine, Kawasaki,
Kanagawa 216-8511, Japan
3Department of Integrative Physiology, Gunma University School of Medicine,
Maebashi, Gunma 371-8511, Japan
Address all correspondence to: Akira Takeshita, MD, PhD Endocrine Center, Toranomon Hospital and Okinaka Memorial Institute for Medical Research
2-2-2 Toranomon, Minato, Tokyo 105-8470, Japan
19 FAX: +81-3-3582-7068
E-mail: coactivator@mac.com
20 21 22 23 24 25
Abbreviated title: Mitotane causes drug-drug interactions
Keywords: mitotane, CYP3A4, SXR, adrenocortical carcinoma
Abstract
Adrenocortical carcinoma (ACC) is a rare disease with an extremely poor prognosis. Mitotane alone or in combination with other cytotoxic drugs is a common therapeutic option for ACC. In addition to its adrenolytic function, mitotane has been known for decades to increase the metabolic clearance of glucocorticoids. It was recently shown that the tyrosine kinase inhibitor sunitinib is also rapidly metabolized in patients treated with mitotane, indicating that mitotane engages in clinically relevant drug interactions. Although the precise mechanism of these interactions is not well understood, cytochrome P450 mono-oxygenase 3A4 (CYP3A4) is a key enzyme to inactivate both glucocorticoids and sunitinib. The nuclear receptor, steroid and xenobiotic receptor (SXR), is one of the key transcriptional regulators of CYP3A4 gene expression in the liver and intestine. A variety of xenobiotics binds to SXR and stimulates transcription of xenobiotic-response elements (XREs) located in the CYP3A4 gene promoter. In the present study, we evaluated the effects of mitotane on SXR-mediated transcription in vitro by luciferase reporter analysis, SXR-steroid receptor coactivator 1 (SRC-1) interactions, quantitative real-time PCR analysis of CYP3A4 expression, SXR knockdown, and CYP3A4 enzyme activity assays using human hepatocyte-derived cells. We found that mitotane activated SXR-mediated transcription of the XREs. Mitotane recruited SRC-1 to the ligand-binding domain of SXR. Mitotane increased CYP3A4 mRNA levels, which was attenuated by SXR knockdown. Finally, we showed that mitotane increased CYP3A4 enzyme activity. We conclude that mitotane can induce CYP3A4 gene expression and suggest that mitotane be used cautiously due to its drug-drug interactions.
26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46
Introduction
Adrenocortical carcinoma (ACC) is a rare disease with an extremely poor prognosis. The annual incidence is approximately 1-2 per million individuals worldwide. At the time of diagnosis, approximately 40-70% of the tumors have already undergone metastatic spread. Even when an apparently radical resection has been performed, eventual local recurrence or distant metastases are often recognized (reviewed in (Allolio and Fassnacht 2006).
Mitotane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl) ethane (o,p’-DDD), is a compound derived from the insecticide dichloro-diphenyl-trichloroethane (DDT), which specifically destroys the adrenal cortex and is able to block cortisol synthesis by inhibiting 11ß-hydroxylation and cholesterol side chain cleavage (Allolio and Fassnacht 2006; Hague, et al. 1989). In patients with metastatic or progressive disease, medical treatment with mitotane is usually begun. In addition to its action on the adrenal cortex, mitotane also affects hepatic microsomal enzyme induction. High-dose glucocorticoid replacement, a daily dose of 50 mg hydrocortisone or greater, is typically required to 60 prevent adrenal insufficiency (Allolio and Fassnacht 2006). The plasma half-life of dexamethasone is shortened among patients who are treated with mitotane (Robinson, et al. 1987). Urinary excretion of 6ß-hydroxycortisol, which is an indicator of hepatic microsomal enzyme induction, is increased in patients after mitotane administration (Fukushima, et al. 1971).
The hepatic cytochrome P450 enzymes (CYPs) catalyze the 6ß-hydroxylation of steroid hormones. CYP3A4 is the most abundant CYP expressed in human liver and is involved in the metabolism of approximately one-half of the drugs in clinical use today. Recently, van Erp et al. reported that mitotane-treated ACC patients exhibited high levels of induced CYP3A4 activity (van Erp, et al. 2011). These authors used orally administered midazolam as a phenotypic probe to determine the activity of CYP3A4. In their pharmacokinetic study using time-course measurement of plasma concentrations, mitotane-treated patients showed an approximate 18-fold reduced exposure to midazolam (AUC0-12 h) but an approximate 12-fold increased exposure to its metabolite, 1-hydroxy midazolam. Furthermore, they observed that the tyrosine kinase inhibitor sunitinib, which is a
47 48 49 50 51 52 53 54 55 56 57 58 59
61 62 63 64 65 66 67 68 69 70 71 72
substrate of CYP3A4, was rapidly metabolized in patients treated with mitotane. However, the precise mechanism of CYP3A4 induction by mitotane is not well understood.
The orphan nuclear receptor, steroid and xenobiotic receptor (SXR; also called the pregnane X receptor, NR1I2), is highly expressed in the liver and intestine where it regulates genes that control 77 xenobiotic and endogenous steroid hormone metabolism. SXR binds to xenobiotic-response elements (XREs) located in the promoters of genes that encode phase I cytochrome P450 (CYP) enzymes (e.g., CYP3A4), phase II conjugating enzymes [e.g., UDP glucuronosyltransferase 1A1 (UGT1A1)], and 80 phase III drug transporters [e.g., P-glycoprotein/multidrug resistance protein 1 (MDR1)] (Kliewer, et al. 2002; Zhang, et al. 2008; Zhou, et al. 2009). Induction of such drug-metabolizing genes by SXR can cause drug-drug interactions. For example, the antibiotic rifampicin (RFP) is a well-known SXR agonist that reduces plasma concentrations of co-administered drugs metabolized by CYP3A4, such as glucocorticoid derivatives, calcium channel blockers, oral contraceptives, and cyclosporine. In the present study, we tested whether mitotane induces CYP3A4 gene expression via SXR activation.
Materials and Methods
Materials
RFP was obtained from Sigma-Aldrich (St Louis, MO, USA). Mitotane was from WAKO Pure Chemical Industries, Ltd (Osaka, Japan), and 6-(4-Chlorophenyl)imidazo[2,1-b] [1,3]thiazole-5-carbaldehyde O-3,4- dichlorobenzyl) oxime (CITCO) was obtained from Enzo Life Sciences, Inc. (Farmingdale, NY, USA). Cryopreserved HepaRG™ cells and cryopreserved human hepatocytes of donor A (batch number HEP187186, 58-year-old man) were purchased from Biopredic International (Rennes, France). Cryopreserved human hepatocytes of donor B (lot LMP, 38-year-old female Caucasian) were purchased from In Vitro Technologies, Inc. (Baltimore, MD, USA).
Plasmids
Human SXR, GAL4 SRC-1-RID, VP16 SXR-LBD, and VP16 SXR-AAF2 LBD expression plasmids were described previously (Takeshita, et al. 2011; Takeshita, et al. 2006). The luciferase (LUC) reporter construct, 5X upstream activating sequence (UAS)-thymidine kinase minimum
73 74 75 76
78 79 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100
promoter (TK)-LUC (Cohen, et al. 2000), and xenobiotic-responsive enhancer module (XREM)-CYP3A4-LUC (Goodwin, et al. 1999) were described previously. Plasmid phRL-TK, which contains the Renilla LUC gene with the TK promoter, was purchased from Promega (Madison, WI, USA).
Transient co-transfection experiments
HepG2 cells were grown in Dulbecco’s modified Eagle medium containing 10% fetal calf serum. The serum was stripped of hormones by constant mixing with 10% (w/v) AG1-X8 resin (Bio-Rad, Hercules, CA, USA) and powdered charcoal prior to ultrafiltration. Cells were maintained without antibiotics and were transiently transfected using the calcium phosphate coprecipitation method in 24-well plates with 0.5 µg reporter plasmid containing either XREM-CYP3A4-LUC or 5X UAS-TK-LUC cDNA and the 0.1-ug human SXR expression plasmid. One hundred nanograms of phRL-TK was used as an internal control. In some samples, empty mock vectors were added to equalize the concentration of total transfected plasmid. Cells were grown for 24 h in the absence or presence of compounds and then harvested. Cell extracts were analyzed for luciferase activity using the Dual-Luciferase Reporter Assay System (Promega). The firefly luciferase activity of the reporter plasmid was corrected by the Renilla luciferase activity of the control plasmid. The corrected luciferase activities of untreated samples were normalized to the luciferase activities of samples as described in the figure legends. All transfection studies were repeated in triplicate. The results shown are the means ± SD (n=3).
Cell culture
Differentiated HepaRG cells were seeded into collagen I-coated 96-well plates using HepaRG Thawing and Seeding Medium 670 (Biopredic International), according to the manufacturer’s instructions. After 3 days, the culture medium was changed to HepaRG Induction Medium 640 (Biopredic International) containing either mitotane or RFP dissolved in dimethyl sulfoxide [DMSO; final concentration 0.1% (v/v)]. The control group received 0.1% DMSO only. Human hepatocytes from donor A were seeded into collagen I-coated 96-well plates with using Hepatocyte Seeding
101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128
Medium (Biopredic International), according to the manufacturer’s instructions. After 24 h, the medium was changed to Hepatocyte Culture Medium (Biopredic International) containing mitotane, RFP, or CITCO dissolved in 0.1% DMSO. Human hepatocytes from donor B were cultured in collagen-coated 12-well plates with Lanford medium. After a 24-h incubation, the cells were treated with either mitotane or RFP dissolved in 0.1% DMSO.
Quantitative real-time PCR (qRT-PCR)
HepaRG cells and human hepatocytes from donor A were analyzed with Power SYBR Green Cells-to-Ct (Applied Biosystems, Foster City, CA, USA) using a PE-Applied Biosystems Prism 7700 instrument. For human hepatocytes from donor B, total RNA was prepared using the TRIzol reagent (Invitrogen) according to the manufacturer’s protocol. RNA was reverse-transcribed using random hexamers and TaqMan reagents (Applied Biosystems). With the resulting cDNA as a template, qRT-PCR was performed using Power SYBR Green PCR Master Mix (Applied Biosystems) and gene-specific primers. The following primers were used for CYP3A4: forward primer
| 5'-CATTCCTCATCCCAATTCTTGAAGT-3', | reverse | primer | ||
|---|---|---|---|---|
| 5'-CCACTCGGTGCTTTTGTGTATCT-3'; | for | CYP2B6: | forward | primer |
| 5'-GGAAAACGATTCCACTACCAAG-3', | reverse | primer | ||
| 5'-AGAAGCCAGAGAAGAGCTCAAA-3'; | for | UGT1A1: | forward | primer |
5’-GAATCAACTGCCTTCACCAAA-3’, reverse primer 5’-ACCACAATTCCATGTTCTCCA-3’; for SXR: forward primer 5’-ACATGTTCAAAGGCATCATCAG-3’, reverse primer
5’-ATCTCAGTTGACACAGCTCGAA-3’; for CAR: forward primer 5’-TGATCAGCTGCAAGAGGAGA -3’, reverse primer 5’-AGGCCTAGCAACTTCGCATA-3’; and for glyceraldehyde 3-phosphate dehydrogenase (GAPDH): forward primer 5’-GGCCTCCAAGGAGTAAGACC-3’, reverse primer 5’-AGGGGAGATTCAGTGTGGTG-3’. Results were normalized with GAPDH using the 2-44Ct method and expressed relative to the untreated control. Representative results are expressed as the mean ± SD (n=3 wells per treatment) of two independent experiments.
129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156
RNAi
HepaRG cells or human hepatocytes from donor A were cultured in collagen I-coated 96-well plates. The cells were transfected with 5 nM Silencer Select predesigned siRNA (Ambion, Austin, TX) against human SXR (s16909) or human CAR (s19369) or with the negative control siRNA (control No. 1). Introduction of the siRNA was carried out using Lipofectamine RNAiMAX (Invitrogen) and the reverse transfection method, according to the manufacturer’s instructions. After 24 h, cells were treated with the test compounds. After 48 h, CYP3A4, CYP2B6, and UGT1A1 expression were determined by qRT-PCR.
CYP3A4 activity
To determine the effects of test compounds on CYP3A4 activity in HepaRG cells, we used the P450-Glo CYP3A4 Assay with Luciferin-IPA (Promega) according to the manufacturer’s instructions. Briefly, HepaRG cells were grown in HepaRG Induction Medium 640 containing mitotane or RFP dissolved in 0.1% DMSO. Cell culture medium without cells served as the background control. After a 48-h treatment, cells were incubated with 3 uM Luciferin-IPA in HepaRG Induction Medium 640 for an additional 60 min. An aliquot of the medium was then combined with an equal volume of the luciferin detection reagent in a white luminometer plate, and the luminescence was read. The remaining cells were assessed using the Cell Titer-Glo Luminescent Cell Viability Assay (Promega) to estimate the number of cells in each well, and CYP3A4 activity was normalized to cell number. Results are expressed as the mean ± SD (n=3).
Statistical analysis
Groups were compared by the Mann-Whitney U-test; p < 0.05 was considered significant in all cases. Statistical analysis was carried out with StatView 5.0 software for Macintosh (SAS Institute, Cary, NC, USA).
157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182
Results
To determine whether mitotane stimulates SXR-mediated transcription of the CYP3A4 gene, transient transfection assays were performed with a reporter plasmid, XREM-CYP3A4-LUC, containing the enhancer (nucleotides -7836 to -7208) and promoter (nucleotides -362 to +53) regions of CYP3A4 to drive luciferase gene expression (Goodwin et al. 1999) in HepG2 cells. A previous 188 study identified four putative SXR response elements within the XREM; three of the four elements cooperatively promote RFP induction by SXR (Goodwin et al. 1999). As shown in Figure 1, mitotane, as well as RFP, increased transcription of the CYP3A4 gene in a dose-dependent manner, although the magnitude of the activation by mitotane was less than that of RFP. Co-transfection of the human SXR plasmid further enhanced transcriptional activation, consistent with previous reports of the relative low expression of endogenous SXR in this cell line (Naspinski, et al. 2008; Zucchini, et al. 2005). This reporter assay suggests that mitotane binds to SXR as a ligand and then stimulates CYP3A4 transcription.
Transcriptional activation by nuclear receptors (NRs) is mediated by ligand-dependent interactions with coactivators, including p160 of the NR coactivator family (SRC1, also called NCOA1; TIF2, also called SRC2, GRIP1, or NCOA2; and TRAM1, also called SRC3, p/CIP, AIB1, ACTR, RAC3, or NCOA3) (Smith and O’Malley 2004). To examine the ligand-induced interactions between SXR and the p160 coactivators, we employed one representative of p160, SRC-1, in mammalian two-hybrid assays. The receptor-interacting domain (RID) of SRC-1 was fused to the DNA-binding domain of GAL4 (GAL4 SRC-1-RID), and the ligand-binding domain (LBD) of human SXR was fused to the transactivation domain of VP16 (VP16 SXR-LBD). These constructs were co-transfected with a reporter plasmid containing five copies of a GAL4 UAS in HepG2 cells (Fig. 2). GAL4 SRC-1-RID interacted with VP16 SXR-LBD in the presence of mitotane as well as RFP in a dose-dependent manner. The C-terminal region of the LBD (AF-2) is conserved among NRs, and deletion or point mutations in this region impair transcriptional activation without changing either ligand- or DNA-binding affinities. Ligands of NRs induce major conformational changes in the AF-2 region so that ligand-bound receptors interact with coactivators (Smith and O’Malley 2004). When the C-terminal-truncated AF2 mutant VP16 SXR-AAF2 was used, neither RFP nor mitotane increased
183 184 185 186 187
189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
luciferase activity, suggesting that mitotane-bound SXR recruits coactivators in an AF2-dependent manner.
To determine whether mitotane induces CYP3A4 expression in the liver, HepaRG cells (Fig. 3A-C) (Kanebratt and Andersson 2008) and cryopreserved human hepatocytes of two donors (donor A: Fig. 3D-F; donor B: Fig. 3G-I) were treated with either RFP or mitotane for 24 or 48 h. CYP3A4 mRNA levels were then determined by qRT-PCR. As shown in Figure 3A, D, and G, both mitotane and RFP increased CYP3A4 mRNA levels in these human hepatocyte-derived cells. Although mitotane had a smaller effect than RFP, apparent CYP3A4 induction by mitotane was observed at concentrations exceeding 10 uM. In addition, both RFP and mitotane increased mRNA levels of CYP2B6 (Fig. 3B, E, and H) and UGT1A1 (Fig. 3C, F, and I). Interestingly, the effect of mitotane on CYP2B6 mRNA levels was higher with than that of RFP in HepaRG cells (Fig. 3B) and donor A hepatocytes (Fig. 3E).
To confirm that mitotane induction of CYP3A4 in human hepatocyte-derived cells requires SXR, we evaluated the effects of SXR knockdown on mitotane-induced gene expression in HepaRG cells (Fig. 4A). After a 24-h transfection with control or SXR-specific siRNA, the cells were treated with 10 uM RFP, 10 uM mitotane, or DMSO (vehicle) for 48 h, and gene expression was analyzed by qRT-PCR. Transfection of gene-specific siRNA reduced SXR mRNA levels by 67% (Data Not Shown). CYP3A4 mRNA levels increased in cells transfected with control siRNA after treatment with RFP or mitotane. However, SXR knockdown suppressed CYP3A4 induction by RFP (from 105.1-fold to 9.8-fold) and mitotane (from 30.5-fold to 4.2-fold), suggesting that SXR is a key regulator of mitotane-induced CYP3A4 expression. In contrast, knockdown of SXR only partially suppressed mitotane induction of CYP2B6 (Fig. 4B) and UGT1A1 (Fig. 4C), whereas RFP induction of these genes was markedly reduced. This finding suggests that mitotane induction of CYP2B6 and UGT1A1 in HepaRG cells can be mediated by a pathway other than SXR. The orphan nuclear receptor (NR) constitutive androstane receptor (CAR; also called NR1I3) is a sister receptor of SXR, and shares a number of the same targets. CAR also has distinct target genes and many chemical activators (Gao and Xie 2010; Tolson and Wang 2010). As shown in Fig. 4D-F, donor A hepatocytes were transfected with siRNAs against CAR and SXR. In this experiment, 1 µM CITCO was used as a positive control
211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238
239 ligand for human CAR (Maglich, et al. 2003). Transfection of gene-specific siRNAs reduced SXR mRNA levels by 73% and CAR mRNA levels by 74% (Data Not Shown). Similar to results observed in HepaRG cells, SXR knockdown in donor A hepatocytes markedly reduced mitotane-induced expression of CYP3A4 (Fig. 4D) but not CYP2B6 (Fig. 4E), whereas RFP-induced expression of both genes was suppressed. In agreement with previous reports, CITCO demonstrated preferential induction of CYP2B6 (Fig. 4E, control siRNA) over CYP3A4 (Fig. 4D, control siRNA). As expected, CAR siRNA but not SXR siRNA abrogated CYP2B6 induction by CITCO (Fig. 4E). Similarly, CAR knockdown significantly reduced mitotane-induced CYP2B6 expression (from 5.3-fold to 1.6-fold) (Fig. 4E), indicating that CAR is a key regulator of mitotane-induced CYP2B6 expression. Both SXR and CAR knockdown reduced mitotane-induced UGT1A1 expression (Fig. 4F). Taken together, our results suggest that mitotane induction of CYP3A4 is mediated primarily by SXR, mitotane induction of CYP2B6 is mediated primarily by CAR, and mitotane induction of UGT1A1 is mediated by both SXR and CAR.
To determine the effects of mitotane on CYP3A4 enzymatic activity in HepaRG cells, we used an assay kit containing Luciferin-IPA. This substrate is metabolized specifically by CYP3A4 to release luciferin, which can be quantified by luminescence through its reaction with ATP-luciferase. HepaRG cells were treated for 48 h with different concentrations of RFP or mitotane. Mitotane increased CYP3A4 activity in a dose-dependent manner, although the magnitude of mitotane-induced CYP3A4 activity was lower than that induced by RFP (Fig. 5).
Discussion
In patients with ACC in whom surgical cure is not possible, mitotane, either as a single agent or in combination with other traditional cytotoxic chemotherapies, is generally administered. Adverse effects of mitotane, such as gastrointestinal distress, neurological disturbances, hepatotoxity, and adrenal insufficiency are well known. Although it has been known for decades that mitotane increases the metabolic clearance of glucocorticoids, drug-drug interactions had not been clearly documented until the recent report by van Erp et al. (van Erp et al. 2011). Our results indicate that mitotane can activate SXR and possibly contribute to the increase in CYP3A4.
240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266
A wide variety of xenobiotics can bind to SXR as ligands and stimulate SXR-mediated transcription. X-ray crystallographic studies of the LBD of human SXR revealed that SXR contains a relatively large ligand-binding pocket compared with other NRs (Watkins, et al. 2001). In addition, the crystal structure of SXR with one of its ligands, SR12813, revealed that a single drug molecule could be bound in the LBD in three distinct orientations (Watkins et al. 2001). The flexibility of the LBD likely enables SXR to recognize a wide range of xenobiotics, including mitotane. It is noteworthy that DDT, from which mitotane is derived, has been reported to be a potent activator of human SXR as well (Medina-Diaz, et al. 2007; Medina-Diaz and Elizondo 2005). Thus, mitotane-bound SXR recruits p160 coactivators to induce CYP3A4 gene expression.
In clinical usage, it is recommended that mitotane blood levels be maintained between 14 and 20 µg/ml (i.e., 43.7-62.5 uM) to achieve tumor regression and avoid adverse effects. Mitotane, at all measured endpoint levels, significantly increased CYP3A4 activity. Although our in vitro assays may not appropriately reflect the in vivo situations of patients treated with mitotane, the concentration of mitotane used in our in vitro studies is certainly achievable pharmacologically in vivo.
CYP3A4 is not only a liver enzyme induced by mitotane. A case report previously described the hypoprothrombinemic effects of warfarin, a substrate of CYP2C9, during mitotane treatment (Cuddy and Loftus 1986). In the present study, we showed that mitotane induces CYP2B6 and UGT1A1 as well as CYP3A4 in human liver-derived cells. CYP2B6 contributes 2% to 10% of total hepatic CYP content and 3% to 12% of drug metabolism capacity (Wang and Tompkins 2008). Known substrates of CYP2B6 include the anticancer drugs cyclophosphamide and ifosfamide, antiretroviral drugs nevirapine and efavirenz, anesthetic drugs propofol and ketamine, the synthetic opioid methadone, and the anti-Parkinson drug selegiline (Wang and Tompkins 2008). UGT1A1, one of the most extensively characterized UGT isoforms, is an enzyme of the glucuronidation pathway, which transforms a diverse range of lipophilic xenobiotics and endogenous compounds (e.g., drugs, environmental chemicals, carcinogens, vitamins, bilirubin, steroid hormones, thyroid hormones, and glycolipids) into water-soluble, excretable metabolites (Tolson and Wang 2010). Therefore, CYP2B6 and UGT1A1 possess important functions in human drug metabolism.
267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293
Results of our knockdown experiments suggest that CAR participates in mitotane-induced CYP2B6 and UGT1A1 activation, whereas mitotane-induced CYP3A4 activation appears to be largely explained by SXR. CAR and SXR regulate an overlapping set of xenobiotic-metabolizing genes, including genes that encode several CYP enzymes (i.e., CYP3A4, CYP2B6, CYP2Cs, and CYP2A6), UGTs (i.e., UGT1A1, UGT1A6, and UGT1A9), and the drug transporter MDR1 (Tolson and Wang 2010). In contrast to most NRs, CAR displays high constitutive activity in the absence of agonist binding but can also be directly activated by ligands (e.g., CITCO) or indirectly activated (e.g., by phenobarbital). In liver cells, CAR is found predominantly in the cytoplasm in the absence of CAR activators but translocates into the nucleus after exposure to phenobarbital-type compounds (Tolson and Wang 2010). Therefore, it will be interesting to know whether mitotane activates CAR by direct ligand binding or nuclear translocation. Further study is necessary to address this issue.
The present study suggests that the concomitant administration of mitotane with anti-cancer drugs metabolized by such as CYP3A4 and CYP2B6 may result in subtherapeutic plasma concentrations of these drugs due to the clinically relevant acceleration of their clearance. In fact, a pharmacokinetic study of sunitinib, a substrate of CYP3A4, in mitotane-treated patients showed its rapid clearance (van Erp et al. 2011). As discussed in a recent review of mitotane drug interactions (Kroiss, et al. 2011), clinical trials of several small-molecule antineoplastic agents, including two epidermal growth factor inhibitors (gefitinib and erlotinib) and the tyrosine kinase inhibitor imatinib (all three are substrates of CYP3A4), resulted in either no or only minor responses to metastases. Importantly, the majority of these patients were treated either previously or concomitantly with mitotane. On the other hand, recent results of the first international randomized trial of locally advanced and metastatic adrenocortical carcinoma treatment (the FIRM-ACT study) showed that the combination regimen of mitotane and etoposide, doxorubicin, and platinum (EDP) had a higher response rate than that of the combination of mitotane and streptozocin, even though both etoposide and doxorubicin are substrates of CYP3A4 (Fassnacht, et al. 2012). Additionally, no one has shown that EDP toxicity is decreased when used in combination with mitotane. Therefore, therapeutic drug monitoring is needed to clarify this issue, which may in turn improve chemotherapy outcomes for patients with ACC (Kroiss et al. 2011).
294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321
In conclusion, our in vitro study shows that mitotane induces CYP3A4 gene expression via the activation of SXR, explaining the many clinical observations of the drug-drug interactions caused by mitotane. Careful therapeutic drug monitoring may therefore lead to improved outcomes and prognoses for patients with ACC.
Declaration of Interest
We declare that there are no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.
Funding
This work was supported by Grants-in-Aid for Scientific Research (C: grant number 22591020 to A.T. and B: grant number 80234681 to N.K.) from the Japan Society for the Promotion of Science and the Okinaka Memorial Institute for Medical Research to A.T.
Acknowledgements
We thank Dr Paul M. Yen (Duke-NUS Graduate Medical School, Singapore) for helpful discussion.
References
Allolio B & Fassnacht M 2006 Clinical review: Adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology & Metabolism 91 2027-2037.
Cohen RN, Putney A, Wondisford FE & Hollenberg AN 2000 The nuclear corepressors recognize distinct nuclear receptor complexes. Mol Endocrinol 14 900-914.
Cuddy PG & Loftus LS 1986 Influence of mitotane on the hypoprothrombinemic effect of warfarin. South Med J 79 387-388.
Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, et al. 2012 Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366 2189-2197.
322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349
Fukushima DK, Bradlow HL & Hellman L 1971 Effects of o,p’-DDD on cortisol and 6-beta-hydroxycortisol secretion and metabolism in man. Journal of Clinical Endocrinology & Metabolism 32 192-200.
Gao J & Xie W 2010 Pregnane X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism. Drug Metab Dispos 38 2091-2095.
Goodwin B, Hodgson E & Liddle C 1999 The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56 1329-1339.
Hague RV, May W & Cullen DR 1989 Hepatic microsomal enzyme induction and adrenal crisis due to o,p’DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol (Oxf) 31 51-57.
Kanebratt KP & Andersson TB 2008 HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 36 137-145.
Kliewer SA, Goodwin B & Willson TM 2002 The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23 687-702.
Kroiss M, Quinkler M, Lutz WK, Allolio B & Fassnacht M 2011 Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 75 585-591.
Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM, et al. 2003 Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem 278 17277-17283.
Medina-Diaz IM, Arteaga-Illan G, de Leon MB, Cisneros B, Sierra-Santoyo A, Vega L, Gonzalez FJ & Elizondo G 2007 Pregnane X receptor-dependent induction of the CYP3A4 gene by o,p’-1,1,1,-trichloro-2,2-bis (p-chlorophenyl)ethane. Drug Metabolism & Disposition 35 95-102.
Medina-Diaz IM & Elizondo G 2005 Transcriptional induction of CYP3A4 by o,p’-DDT in HepG2 cells. Toxicology Letters 157 41-47.
Naspinski C, Gu X, Zhou GD, Mertens-Talcott SU, Donnelly KC & Tian Y 2008 Pregnane X receptor protects HepG2 cells from BaP-induced DNA damage. Toxicol Sci 104 67-73.
350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377
Robinson BG, Hales IB, Henniker AJ, Ho K, Luttrell BM, Smee IR & Stiel JN 1987 The effect of o,p’-DDD on adrenal steroid replacement therapy requirements. Clinical Endocrinology 27 437-444.
Smith CL & O’Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25 45-71.
Takeshita A, Igarashi-Migitaka J, Nishiyama K, Takahashi H, Takeuchi Y & Koibuchi N 2011 Acetyl tributyl citrate, the most widely used phthalate substitute plasticizer, induces cytochrome p450 3a through steroid and xenobiotic receptor. Toxicol Sci 123 460-470.
Takeshita A, Inagaki K, Igarashi-Migitaka J, Ozawa Y & Koibuchi N 2006 The endocrine disrupting chemical, diethylhexyl phthalate, activates MDR1 gene expression in human colon cancer LS174T cells. Journal of Endocrinology 190 897-902.
Tolson AH & Wang H 2010 Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev 62 1238-1249.
van Erp NP, Guchelaar HJ, Ploeger BA, Romijn JA, Hartigh J & Gelderblom H 2011 Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol 164 621-626.
Wang H & Tompkins LM 2008 CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9 598-610.
Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, Williams SP, Willson TM, Kliewer SA & Redinbo MR 2001 The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292 2329-2333.
Zhang B, Xie W & Krasowski MD 2008 PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9 1695-1709.
Zhou C, Verma S & Blumberg B 2009 The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl Recept Signal 7 e001.
Zucchini N, de Sousa G, Bailly-Maitre B, Gugenheim J, Bars R, Lemaire G & Rahmani R 2005 Regulation of Bcl-2 and Bcl-xL anti-apoptotic protein expression by nuclear receptor PXR in primary cultures of human and rat hepatocytes. Biochimica et Biophysica Acta 1745 48-58.
378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405
Figure Legends
Figure 1. Mitotane activates SXR-mediated transcription of the CYP3A4 promoter in HepG2 cells. HepG2 cells were co-transfected with the reporter plasmid, 0.5 µg XREM-CYP3A4-LUC, 0.1 ug 411 human SXR expression plasmid (right), or empty mock plasmid (left), and the phRL-TK control vector (0.1 µg). Cells were treated with different doses of RFP or mitotane for 24 h and analyzed for luciferase activity. The firefly luciferase activity from the reporter plasmid was normalized to Renilla luciferase activity from the control plasmid with 1-fold basal activity defined as luciferase activity in the absence of ligand and exogenous SXR. The results are expressed as the means ± SD (n=3).
Figure 2. Mitotane recruits SRC-1 to the LBD of SXR in HepG2 cells.
The expression plasmids encoding GAL4 SRC-1-RID (0.1 ug) and VP16 mock (left), VP16 SXR-LBD (center), or VP16 SXRAAF2-LBD (right) (0.5 µg) were co-transfected with the 5X UAS-TK-LUC reporter plasmid (0.5 µg) and the phRL-TK control vector (0.1 ug) in HepG2 cells. Cells were treated with 1 or 10 uM RFP or mitotane for 24 h. The corrected luciferase activity was calculated as fold luciferase activity with 1-fold basal activity defined as luciferase activity of GAL4 SRC-1-RID and VP16 mock plasmids in the absence of ligand. The results are expressed as the mean ± SD (n=3).
Figure 3. Mitotane induces drug metabolism genes in human liver.
HepaRG cells (A-C) and human hepatocytes from donor A (D-F) were treated with RFP (0.1, 1, 10, or 20 uM), mitotane (0.1, 1, 10, 20, 30, or 40 uM), or 0.1% DMSO (vehicle control) for 48 h. (G-I) Human hepatocytes from donor B were treated with 10 uM RFP, 20 uM mitotane, or 0.1% DMSO (vehicle control) for 24 h. Expression levels of CYP3A4 (A, D, and G), CYP2B6 (B, E, and H), and UGT1A1 (C, F, and I) were analyzed by qRT-PCR, normalized to GAPDH, and expressed relative to
406 407 408 409 410
412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433
the DMSO control. Results are expressed as mean + SD (n=3); * p < 0.05 versus control.
Figure 4. Mitotane induces CYP3A4 expression in human liver cells by activating SXR.
HepaRG cells (A-C) were transfected with control siRNA or SXR siRNA and treated with 10 uM RFP, 10 uM mitotane, or 0.1% DMSO (vehicle control) for 48 h. Human hepatocytes from donor A (D-F) were transfected with control siRNA, SXR siRNA, or CAR siRNA and then treated with 10 uM RFP, 10 uM mitotane, 1 µM CITCO, or 0.1% DMSO (vehicle control) for 48 h. Expression levels of CYP3A4 (A and D), CYP2B6 (B and E), and UGT1A1 (C and F) were analyzed by qRT-PCR, normalized to GAPDH, and expressed relative to the DMSO control. Results are expressed as mean ± 444 SD (n=3).
Figure 5. Mitotane induces CYP3A4 enzymatic activity in HepaRG cells.
HepaRG cells were treated with different doses of RFP, mitotane, or 0.1% DMSO (vehicle control). After 48 h, the medium was replaced with medium containing 4 uM Luciferin-IPA, and cells were incubated for an additional 60 min. An aliquot of the medium was combined with an equal volume of P450-Glo Luciferin Detection Reagent, and luminescence was read on a Lumat LB9507 luminometer. CYP3A4 activity was normalized to the number of cells and expressed relative to the DMSO control. Results are presented as the mean ± SD (n=3).
434 435 436 437 438 439 440 441 442 443 445 446 447 448 449 450 451 452 453
70
Relative Luciferase Activity
☐ Control
60
☐ RFP 1,3,10,30 μΜ
☒ Mitotane 1, 3, 10, 30 µM
50
40
30
20
10
0
Mock plasmid
hSXR plasmid
Relative Luciferase Activity
35
☐ Control
30
☐ RFP
1,10 μΜ
☒ Mitotane 1, 10 µM
25
20
15
10
5
0
GAL4
SRC1 + Mock
SRC1
SRC1 +
+
VP16
SXR-LBD
SXRAAF2-LBD
254×175mm (72 × 72 DPI)
CYP3A4 / GAPDH mRNA
100
120
60
80
A
40
20
0
CYP3A4 / GAPDH mRNA
Control
0.1 µM
15
1 pM
0
D
10 pM
DMSO
20 pM
Mitotane
RFP
on
0.1 PM
0
CYP3A4 / GAPDH mRNA
1 pM
CYP2B6 / GAPDH mRNA
Control
10 PM
20
0.1 µM
20 PM
A
16
1
1 µM
30 PM
DMSO
40 PM
A
1
G
10 µM
20 µM
RFP
B
Mitotane
A
0.1 µM
Q
N
CYP2B6 / GAPDH mRNA
HepaRG
0
1 µM
10 μM
Control
Control
0.1 µM
30 µM
30
40 µM
·
25
1 pM
E
10 PM
RFP
DMSO
15
20 pM
10 µM
10
CYP3A4
Mitotane
U
Donor A
0.1 PM
O
1 pM
CYP2B6 / GAPDH mRNA
UGT1A1 / GAPDH mRNA
Control
10 PM
9
20 µM
6
0.1 µM
30 PM
1 µM
40 pM
P
0
1
H
10 µM
2
20 µM
₼
1
0
Donor B
0.1 µM
0
1 µM
UGT1A1 / GAPDH mRNA
Control
10 µM
Control
20 µM
0
0.1 µM
30 PM
8
9
1 pM
254×175mm (72 x 72 DPI)
40 µM
A
10 pM
P
20 pM
10 µM
2
0.1 PM
CYP2B6
0
1 pM
UGT1A1 / GAPDH mRNA
Control
10 PM
20 PM
20 µM
5
0.1 µM
30 PM
4
1 µM
40 PM
10 µM
2
20 µM
A
0.1 µM
C
1 PM
10 PM
Control
9
20 M
30 UM
40 PM
UGT1A1
10 µM
20 µM
Fig. 3
CYP3A4 / GAPDH mRNA
CYP2B6 / GAPDH mRNA
HepaRG
20
UGT1A1 / GAPDH mRNA
5
A
DMSO
20
B
C
100
RFP
10 μΜ
Mitotane 10 UM
4
80
15
3
60
10
2
40
20
5
1
0
0
0
Control SIRNA
SXR SİRNA
Control SIRNA
SXR SIRNA
Control SİRNA
SXR SİRNA
CYP3A4 / GAPDH mRNA
Donor A
10
CYP2B6 / GAPDH mRNA
D
20
UGT1A1 / GAPDH mRNA
DMSO
E
5
F
8
RFP
10 μΜ
Mitotane 10 μM
15
4
6
CITCO
1 μΜ
3
10
4
2
2
5
1
0
0
0
Control SİRNA
SXR SİRNA
CAR SİRNA
Control SİRNA
SXR SİRNA
CAR SİRNA
Control SİRNA
SXR SİRNA
CAR SİRNA
CYP3A4
CYP2B6
UGT1A1
Fig. 4
Fold Induction (CYP3A4)
20
15
10
5
0
☐
Control ☐
☒ ☐ RFP
DMSO
0.3 µM
Mitotane
1 µM
3 µM
10 µM
20 µM
0.3 µM
1 µM
3 HM 10 µM
20 µM
40 µM
254×175mm (72 × 72 DPI)